Breaking News Instant updates and real-time market news.

GS

Goldman Sachs

$179.71

-4.44 (-2.41%)

, LYFT

Lyft

$0.00

(0.00%)

06:10
12/10/18
12/10
06:10
12/10/18
06:10

Slack hires Goldman to lead IPO, Reuters reports

Chat provider Slack Technologies has selected investment bank Goldman Sachs (GS) to lead its initial public offering in 2019 as an underwriter, Reuters reports, citing people familiar with the matter. The move comes amid other expected IPOs from Airbnb, Palantir Technologies, Stripe, Lyft (LYFT) and Uber Technologies (UBER) and Slack, which competes with Microsoft's (MSFT) Teams, Google (GOOG, GOOGL) Hangouts Chat and Cisco's (CSCO) Webex Teams, hopes to bring in a valuation well over $10B in its IPO. Reference Link

GS

Goldman Sachs

$179.71

-4.44 (-2.41%)

LYFT

Lyft

$0.00

(0.00%)

UBER

Uber

$0.00

(0.00%)

MSFT

Microsoft

$104.90

-4.27 (-3.91%)

GOOG

Alphabet

$1,036.52

-33.18 (-3.10%)

GOOGL

Alphabet Class A

$1,046.99

-31.41 (-2.91%)

CSCO

Cisco

$46.42

-1.96 (-4.05%)

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 10

    Jan

  • 03

    Mar

GS Goldman Sachs
$179.71

-4.44 (-2.41%)

12/07/18
FBCO
12/07/18
NO CHANGE
Target $35
FBCO
Outperform
Bank of America price target cut to $35 from $36 at Credit Suisse
Credit Suisse analyst Susan Roth Katzke maintained a Neutral rating on Bank of America (BAC) but cut her price target to $35 from $36. In a research note to investors, she says that she has increased the weighting on her "gray sky valuation" to 25% from 15% and reduced the weighting on her "blue sky scenario" to 25% from 35%, and while she does not anticipate an imminent turn in the cycle, she feels she must recognize some increased probability relative to the status quo. For Bank of America, she says organic revenue growth, visible operating leverage, manageable credit cost increases and capital efficiency will drive realization of franchise value. The analyst also lowered her price targets on other large banks, including Morgan Stanley (MS), PNC (PNC), State Street (STT), Goldman Sachs (GS), JPMorgan (JPM) and Wells Fargo (WFC).
12/07/18
FBCO
12/07/18
NO CHANGE
Target $128
FBCO
Outperform
JPMorgan price target cut to $128 from $130 at Credit Suisse
Credit Suisse analyst Susan Roth Katzke maintained an Outperform rating on JPMorgan (JPM) but lowered her price target to $128 from $130. In a research note to investors, she says that she has increased the weighting on her "gray sky valuation" to 25% from 15% and reduced the weighting on her "blue sky scenario" to 25% from 35%, and while she does not anticipate an imminent turn in the cycle, she feels she must recognize some increased probability relative to the status quo. The analyst also lowered her price targets on other large banks, including Morgan Stanley (MS), PNC (PNC), Bank of America (BAC), Goldman Sachs (GS), State Street (STT) and Wells Fargo (WFC).
12/07/18
FBCO
12/07/18
NO CHANGE
Target $60
FBCO
Neutral
Wells Fargo price target cut to $60 from $62 at Credit Suisse
Credit Suisse analyst Susan Roth Katzke maintained a Neutral rating on Wells Fargo (WFC) but cut her price target to $60 from $62. In a research note to investors, she says that she has increased the weighting on her "gray sky valuation" to 25% from 15% and reduced the weighting on her "blue sky scenario" to 25% from 35%, and while she does not anticipate an imminent turn in the cycle, she feels she must recognize some increased probability relative to the status quo. The analyst also lowered her price targets on other large banks, including Morgan Stanley (MS), PNC (PNC), Bank of America (BAC), State Street (STT), Goldman Sachs (GS) and JPMorgan (JPM).
12/07/18
FBCO
12/07/18
NO CHANGE
Target $146
FBCO
Neutral
PNC Financial price target cut to $146 from $150 at Credit Suisse
Credit Suisse analyst Susan Roth Katzke maintained a Neutral rating on PNC Financial (PNC) but cut her price target to $146 from $150. In a research note to investors, she says that she has increased the weighting on her "gray sky valuation" to 25% from 15% and reduced the weighting on her "blue sky scenario" to 25% from 35%, and while she does not anticipate an imminent turn in the cycle, she feels she must recognize some increased probability relative to the status quo. The analyst also lowered her price targets on other large banks, including Morgan Stanley (MS), Bank of America (BAC), State Street (STT), Goldman Sachs (GS), JPMorgan (JPM) and Wells Fargo (WFC).
LYFT Lyft
$0.00

(0.00%)

UBER Uber
$0.00

(0.00%)

10/22/18
PIPR
10/22/18
NO CHANGE
Target $85
PIPR
Overweight
Twilio 23% pullback this month a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Alex Zukin recommends using the 23% pullback in Twilio shares this month as a buying opportunity. The analyst left the company's Signal conference believing that the demand environment "remains robust." Floor conversations with employees and sales executives suggest that "morale is high and quotas are attainable," Zukin tells investors in a research note. Further, the conversations also suggested that Uber may be considering engaging with Twilio when it comes to Flex, the analyst adds. He believes that if true, this would be a "big turn of events with regard to the Twilio-Uber relationship and may lead to yet another change in the financial relationship between the two companies." Zukin reiterates an Overweight rating on Twilio with an $85 price target.
MSFT Microsoft
$104.90

-4.27 (-3.91%)

11/26/18
WEDB
11/26/18
NO CHANGE
WEDB
Sony appeared to be video game hardware winner on Black Friday, says Wedbush
Wedbush analyst Michael Pachter notes that each of the four game retailers he tracked, namely Best Buy (BBY), GameStop (GME), Target (TGT) and Walmart (WMT) offered the Marvel's Spider-Man PlayStation 4 Bundle that included a slim PS4 with a 1TB hard drive and Sony's (SNE) Marvel's Spider-Man for $199.99, as well as the Microsoft's (MSFT) Xbox One S Minecraft Creators Bundle that included an Xbox One S with a 1TB hard drive, a Minecraft full game download, the Starter Pack, the Creators Pack, and 1,000 Minecoins for $199.99. Nintendo's (NTDOY) primary hardware offering was less compelling given that it was priced at the console's standard MSRP, he adds. The only sell-out that the analyst saw over Black Friday was the primary PS4 deal. Pachter expects the Black Friday deals to eventually translate into permanent price cuts for the base PS4 and Xbox One, possibly by this Christmas.
11/28/18
JEFF
11/28/18
NO CHANGE
Target $2300
JEFF
Buy
Jefferies pegs potential value of Amazon Web Services at $350B
The momentum of Amazon Web Services is evident with three days still left in the annual re:Invent Cloud conference, Jefferies analyst Brent Thill tells investors in a research note. Enterprise customers are making bigger commitments earlier with AWS, increasing partner deal sizes 3.5 times, says the analyst. He forecasts AWS revenue to hit $71B by 2020, potentially worth $350B versus Amazon's current market capitalization of $800B. Thill believes AWA is competing well against Oracle (ORCL) and Microsoft (MSFT). The analyst keeps a Buy rating on Amazon with a $2,300 price target.
11/29/18
WEDB
11/29/18
NO CHANGE
Target $140
WEDB
Outperform
Wedbush bullish on Microsoft into 2019 given Azure cloud momentum
Wedbush analyst Daniel Ives believes Microsoft remains in an "enviable" position heading into 2019 on the heels of its cloud success and is firing on all cylinders around its Office 365 and Azure strategic vision based on his recent checks. The analyst thinks the shift to cloud is a major secular trend that is significantly benefiting Microsoft in the field as a key tailwind and should continue its momentum heading into the next 12-18 months. Ives is bullish on the stock into 2019 given his thesis that Azure's cloud momentum is still in its early days of playing out with the company's massive installed base, Office 365 transition on consumer/enterprise providing growth tailwinds for the next 12 to 18 months at least, and newer integrated product initiatives around consumers and cloud services are still playing out within Redmond's ubiquitous installed base of consumers and enterprises worldwide. He reiterates an Outperform rating and $140 price target on the shares.
12/03/18
STFL
12/03/18
NO CHANGE
Target $190
STFL
Hold
After proxy, Stifel says Google could come back with bid for Red Hat
After Red Hat (RHT) filed a proxy on Friday evening related to its pending acquisition by IBM (IBM) that mentioned three other parties interested in a potential purchase, Stifel analyst Brad Reback said he believes that "Party A" in the filing is Microsoft (MSFT), that "Party B" is Google (GOOGL) and that "Party C" is Amazon (AMZN). If he is correct with that assessment of the identities of the parties, it is a clear indication that Red Hat shopped itself to the "logical players" during the negotiation process, said Reback, who believes there is still a chance Google may come back and make a bid for Red Hat given the change of leadership in the Google Cloud unit. The analyst, who views Red Hat as a unique asset with strong enterprise relationships, hybrid cloud capabilities, and an open source heritage, keeps a Hold rating and $190 price target on the stock given the existing deal with IBM.
GOOG Alphabet
$1,036.52

-33.18 (-3.10%)

11/26/18
KEYB
11/26/18
NO CHANGE
KEYB
AWS revenue could double to $56B-plus by 2021, says KeyBanc
KeyBanc analyst Brent Bracelin notes that the annual November trek to Las Vegas for AWS (AMZN) reInvent commences on Tuesday. The analyst believes 2019 could mark the first year AWS adds an incremental $10B within a single year as cloud and digital transformation becomes a mainstream phenomena driving AWS revenue to $35B-plus and operating profits above $10B for the first time. Looking out three years to 2021, Bracelin estimates AWS revenue could double to an estimated $56B-plus from $25B this year. Even at that scale, this would assume AWS might capture just 4% share of a trillion-dollar market leaving ample room for IaaS alternative platforms like Microsoft Azure (MSFT) and Google Cloud (GOOG; GOOGL) to also sustain high-growth at scale, he contends. Bottom line, the analyst believes AWS is likely to remain a bright spot within the broad Amazon product portfolio from both a revenue growth and profitability perspective during a cloud-first era.
12/06/18
GUGG
12/06/18
INITIATION
Target $1330
GUGG
Buy
Alphabet initiated with a Buy at Guggenheim
Guggenheim analyst Michael Morris initiated Alphabet with a Buy and $1,330 price target saying it has a unique combination of intellectual property, employee talent and financial resources that position it well for global growth beyond implied expectations.
12/06/18
12/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. LG Display (LPL) initiated with a Buy at Citi. 2. Twitter (TWTR) and Alphabet (GOOG, GOOGL) were initiated with a Buy at Guggenheim, while Snap (SNAP) and Facebook (FB) were initiated with a Neutral. 3. Apache (APA) initiated with an Overweight at Stephens. 4. CorMedix (CRMD) initiated with a Buy at Roth Capital. 5. Protagonist Therapeutics (PTGX) initiated with a Buy at Nomura Instinet. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GOOGL Alphabet Class A
$1,046.99

-31.41 (-2.91%)

11/26/18
MKMP
11/26/18
NO CHANGE
Target $190
MKMP
Buy
MKM Partners lowers price targets on Alphabet and Facebook
MKM Partners analyst Rob Sanderson lowers his price target on Alphabet (GOOGL) to $1,365 from $1,465 and on Facebook (FB) to $190 from $230 as part of his broader research note for the Internet Applications and Media sector. The analyst states that both of these stocks have been underperforming the Nasdaq on 1-month, 3-month, and year-to-date basis, but believes that Alphabet's underperformance has more to do with a rotation away from growth given its "remarkably consistent" performance and its expected moderating traffic acquisition rate costs. Sanderson says that while Facebook stock is the "furthest from its intrinsic value", it continues to face a "challenging event path with engagement shift toward lower monetizing apps" and the expected cost increase to build greater "safety and security competencies". He also believes that Facebook business model will normalize at "much lower profit margin" because of these added costs. The analyst keeps Alphabet and Facebook ratings at Buy. As part of his research note, Sanderson also maintains a Buy rating on Twitter (TWTR) with a price target of $43. The analyst contends that the company has "compelling upside potential as monetization catches up to engagement growth", with added optionality coming from potential "service breaks-through to the mass market."
CSCO Cisco
$46.42

-1.96 (-4.05%)

12/06/18
JPMS
12/06/18
NO CHANGE
JPMS
JPMorgan adds Cisco to Analyst Focus List, removes Ciena
JPMorgan analyst Samik Chatterjee removed Ciena (CIEN) from his firm's Analyst Focus List following the year-to-date share price performance of 48%. The analyst, however, keeps an Overweight rating on the shares as he still sees 24% upside from current levels. Heading into 2019, he added Overweight-rated Cisco Systems (CSCO) to the Analyst Focus List as a value idea. Cisco is now his top pick within his Networking Equipment/IT Hardware coverage given its "accelerating" product momentum, secular transformation to software and recurring revenue, and potential for "greater upside from re-rating of the shares."
11/29/18
BARD
11/29/18
INITIATION
Target $53
BARD
Outperform
Cisco assumed with an Outperform at Baird
Baird analyst Jonathan Ruykhaver assumed coverage on Cisco with an Outperform rating and $53 price target based on expectations for the company to see a revenue reacceleration. He also cites a new product refresh cycle, a new subscription based model for its Cat 9k model, expected dividend increases and current valuation.
11/15/18
LOOP
11/15/18
NO CHANGE
Target $45
LOOP
Hold
Cisco price target lowered to $45 from $47 at Loop Capital
Loop Capital analyst James Kisner lowered his price target on Cisco to $45 and kept his Hold rating after its "solid" Q1 results. The analyst says that he is positive on the company's "strategic direction and crisp execution of late", but also finds its valuation uncompelling given Cisco's "modest long-term growth prospects". Kisner further contends that Cisco's growth trends are ultimately tied to the global economy, which is recently showing some "pockets of weakness" and will likely result in Catalyst 9K upgrade cycle slowing in the future.
11/15/18
GSCO
11/15/18
NO CHANGE
Target $56
GSCO
Buy
Cisco may be assuming worst case scenario on tariff impacts, says Goldman Sachs
Goldman Sachs analyst Rod Hall notes that Cisco reported a stronger than normal beat of 3c versus consensus in the quarter and guided in line with consensus EPS at 72c at the midpoint. However, the midpoint of revenue guidance implies what he sees as a well below seasonal Q2 to January after the company just delivered a strong performance in Q1. The analyst suspects the company has assumed a worst case scenario on tariff impacts to demand as well as SP spending but he believes better outcomes are not only possible but likely. Additionally, Hall thinks theC at 9K ramp is accelerating and should continue to do so through early 2019. He reiterates a Buy rating and $56 price target on the shares.

TODAY'S FREE FLY STORIES

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

09:22
12/08/19
12/08
09:22
12/08/19
09:22
Hot Stocks
Agios says proof-of-concept has been established for mitapivat »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

ZIOP

Ziopharm

$5.16

0.06 (1.18%)

09:20
12/08/19
12/08
09:20
12/08/19
09:20
Hot Stocks
Ziopharm reports pre-clinical data of Rapid Personalized Manufacture »

Ziopharm Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TGTX

TG Therapeutics

$7.11

-0.57 (-7.42%)

09:18
12/08/19
12/08
09:18
12/08/19
09:18
Hot Stocks
TG Therapeutics reports triple therapy data from Phase I/II study of ublitux »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:16
12/08/19
12/08
09:16
12/08/19
09:16
Hot Stocks
Karyopharm says four posters will be presented at ASH »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPHA

Innate Pharma

$6.30

(0.00%)

09:13
12/08/19
12/08
09:13
12/08/19
09:13
Hot Stocks
Innate Pharma reports long-term data from Phase III trial of Lumoxiti »

Innate Pharma shared new,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$372.26

4.02 (1.09%)

09:11
12/08/19
12/08
09:11
12/08/19
09:11
Hot Stocks
Regeneron reports initial data for REGN5458 in myeloma patients »

Regeneron Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:09
12/08/19
12/08
09:09
12/08/19
09:09
Hot Stocks
Blueprint reports 77% overall response rate in 48 patients from Explorer trial »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:06
12/08/19
12/08
09:06
12/08/19
09:06
Hot Stocks
Blueprint announces initial data from Phase 2 Pioneer trial in mastocytosis »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PCG

PG&E

$9.65

-0.13 (-1.33%)

08:12
12/08/19
12/08
08:12
12/08/19
08:12
Periodicals
PG&E settlement threatens bondholders plan, WSJ reports »

PG&E's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SYRS

Syros Pharmaceuticals

$4.60

-0.02 (-0.43%)

08:08
12/08/19
12/08
08:08
12/08/19
08:08
Hot Stocks
Syros announces fetal hemoglobin repressor using gene control platform »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:06
12/08/19
12/08
08:06
12/08/19
08:06
Hot Stocks
AbbVie says post-hoc analysis supports benefit of venetoclax in combination »

AbbVie presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

08:03
12/08/19
12/08
08:03
12/08/19
08:03
Hot Stocks
Genentech reports data from two Phase III Venclexta studies in leukemia »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

ORTX

Orchard Therapeutics

$11.85

0.37 (3.22%)

07:59
12/08/19
12/08
07:59
12/08/19
07:59
Hot Stocks
Orchard to present data from multiple programs at ASH meeting »

Orchard Therapeutics said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

06:55
12/08/19
12/08
06:55
12/08/19
06:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:31
12/07/19
12/07
19:31
12/07/19
19:31
Hot Stocks
Magenta reports results from MGTA-145 stem cell mobilization program »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29
Hot Stocks
Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis »

The Bristol-Myers…

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Hot Stocks
Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies »

Unum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

19:23
12/07/19
12/07
19:23
12/07/19
19:23
Hot Stocks
Autolus presents new data on T cell therapies in leukemia, lymphoma »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:19
12/07/19
12/07
19:19
12/07/19
19:19
Hot Stocks
Bristol-Myers says lisocabtagene maraleucel study met both endpoints »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.